Mount Sinai Dermatology

We are open for business at our new practice at 533 W 57th Street, 6th Fl, Suite A! We invite patients to come to our new, beautiful location w- state-of-the-art equipment & shiny new exam rooms. Call 212-241-9728 for an appt. #dermatology ⁦⁦⁦@EmmaGuttman⁩

.@EmmaGuttman gave 2 Keynote Lectures: “New Advances in Atopic Dermatitis” & “New Horizons in Hair Loss Disorders” moderated “New Horizons in AD: Therapeutic Evolution" & presented “New Horizons in Derm: Achieving MDA w- JAK inhibition in AD” IASI Dermatology Spring in Romania.

Bimekizumab improves hidradenitis suppurativa using IHS4 outcomes, shown in pooled Phase three BE HEARD I and II trials. Dr. Khattri and colleagues demonstrate reductions in disease severity, with some patients achieving complete resolution 🔗bit.ly/4sap9Jm @emmaguttman

Superiorly based paranasal interpolation folded flap for full thickness alar rim defects after Mohs surgery, reported by Dr. Lewin. Elegant solution restoring nasal support and symmetry while avoiding hair bearing skin transfer. 👃🔬 🔗 bit.ly/4s3quSd @EmmaGuttman

Shruti Naik, PhD, will present “Duplicate Forging a New Therapeutic Frontier at the Intersection of Immunology and Regenerative Medicine” at the Dean’s Select Seminar Series: Monday, April 6, 4-6 pm. Details: bit.ly/DrNaikDeansSem… @DrShrutiNaik @EmmaGuttman

Alopecia Areata Symposium: Towards Better Treatments in AA—A Unique Educational Symposium Join us! When: Thursday, April 23, 2026 | 4:30-8:00 pm Where: Mount Sinai Goldwurm Auditorium, 1425 Madison Ave. 1st FL (at 98th St.) Register now: surveymonkey.com/r/VPMXRR5 @EmmaGuttman

Children aren’t “small adults". A new clinic-to-lab study by Dr. Yue Xing, @DrShrutiNaik @EmmaGuttman & multi-institutional team (Weill Cornell) tackles why eczema begins in childhood & frequently precedes asthma, food allergy & other allergies. Details: bit.ly/3P4OsO0

We are ranked No. 3 in NIH research funding—Dermatology — 2025 by Blue Ridge Institute for Medical Research (BRIMR). A testament to the rigor of our academic research ahead of many premier institutions. From No. 23 (in 2020) to No. 3 = ↗️ growth @EmmaGuttman @IcahnMountSinai

.@EmmaGuttman presented ”Atopic Dermatitis Treatment Update” and was on a Panel Q & A at Masterclasses in Dermatology Annual Meeting in Sarasota, FL. #dermatology #research #MCD2026

Out very own @itchdoctor reframes itch as a neuroimmune circuit, sensory neurons plus immune cells (especially mast cells) amplify type 2 inflammation. Explains how antihistamine limits and highlights next-gen targets, shaping future care. 🔗tinyurl.com/3ekbb5sf @emmaguttman

Dr. Benjamin Ungar, @EmmaGuttman, and colleagues synthesizes AA pathogenesis, diagnosis and severity tools, and the rapidly evolving therapeutic landscape shaped by JAK inhibition, while underscoring unmet needs and relapse risk. 🔗tinyurl.com/aa75284

Dr. Khattri and colleagues report a 22-patient recalcitrant GGA case series treated with biologics and oral JAK inhibitors. Nearly 60% achieved marked response or remission, supporting pathway-informed systemic options. 🔗 bit.ly/4kNpWwP @emmaguttman

According to NEW STUDY, #MajorDepressiveDisorder shares immune abnormalities and potential therapeutic targets with inflammatory skin diseases. Findings provide rationale for targeted strategy that may lead to new personalized treatments. PRESS RELEASE👉 mountsinai.org/about/newsroom…

Brain organoid models may close key gaps in studying melanoma brain metastases by better capturing the human brain microenvironment, Blood Brain Barrier biology, and treatment penetration, in new editorial by Dr. Ji and Dr. Gulati 🔗bit.ly/49yL05c @emmaguttman

Multidisciplinary team @IcahnMountSinai found major depressive disorder shares immune abnormalities w- inflammatory skin diseases eg: atopic dermatitis. Press release: bit.ly/4aMDCVp Details: nature.com/articles/s4138… @EmmaGuttman @JMurrough

Real-world cohort data from Dr. Ungar and colleagues using AI dermoscopic imaging show low-dose oral minoxidil is associated with measurable gains in terminal hair density and thickness by 4 and 8 months. 🔗tinyurl.com/56metkmn @emmaguttman

Analysis by Dr. Lebwohl and colleagues finds atopic dermatitis is associated with higher nonmelanoma skin cancer risk vs matched controls, including moderate-to-severe AD, supporting risk-stratified skin surveillance and UV counseling. 🔗tinyurl.com/3r7nd98p @EmmaGuttman

Dr. Banu Farabi and colleagues review stem cell use across medicine and highlight Dermatology applications, from psoriasis and atopic dermatitis to vitiligo, epidermolysis bullosa, and alopecia. 🔗 bit.ly/3NqSrUp @emmaguttman

Topical delgocitinib 2% in randomized phase 2a FFA trial reduced lesional Th1 signals & shifted scalp transcriptomics —more non-lesional profile, w- clinical improvement & good tolerability, by Dr. @EmmaGuttman Dr. Del Duca, w- Dr. Maryanne Makredes Senna bit.ly/4sLuhEu

Congratulations Dr. Patrick Brunner, appointed to American Skin Association Medical Advisory Committee. 👏 His research in cutaneous lymphomas, AD & vitiligo gives invaluable perspective to ASA’s work advancing derm research & #skinhealth bit.ly/4asBYIq @EmmaGuttman

Refractory atopic dermatitis treated with dual targeting: upadacitinib plus lebrikizumab led to rapid, sustained clearance in a case report by Dr. Lebwohl and Dr. Golant. Signals a potential role for carefully selected combination therapy. 🔗bit.ly/4qcPwNM @emmaguttman